Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1609
    -0.0074 (-0.63%)
     
  • GBP/USD

    1.2370
    -0.0069 (-0.55%)
     
  • Bitcoin GBP

    51,901.48
    +721.25 (+1.41%)
     
  • CMC Crypto 200

    1,380.62
    +68.00 (+5.18%)
     
  • S&P 500

    4,963.67
    -47.45 (-0.95%)
     
  • DOW

    37,925.22
    +149.84 (+0.40%)
     
  • CRUDE OIL

    83.46
    +0.73 (+0.88%)
     
  • GOLD FUTURES

    2,413.10
    +15.10 (+0.63%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

How AbbVie Could Hammer Gilead's Hepatitis C Franchise

How AbbVie Could Hammer Gilead's Hepatitis C Franchise

AbbVie is likely to swipe significant hepatitis C drug share from Gilead Sciences with an eight-week regimen, an analyst said Wednesday.